```
Application Number: 10/821,382
```

RECEIVED CENTRAL FAX CENTER

[4-(difluoropiperazinylmethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

SEP 2 7 2006

{4-[difluoro(4-methylpiperazinyl)methyl]phenyl}-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-({[2-(dimethylamino)ethyl]amino}difluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

(4-{fluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl}-phenyl)-N-{4-methyl-3-[(4-

(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4-[fluoro(pyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4-[(4-ethylpiperazinyl)difluoromethyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-

2-yl)amino]phenyl}carboxamide

{4-[(4-ethylpiperazinyl)fluoromethyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-

2-yl)amino]phenyl}carboxamide

(4-{difluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl}-phenyl)-N-{4-methyl-3-[(4-

(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

 $\{4-[difluoro(methylpyrrolidin-3-ylamino)methyl] phenyl\}-N-\{4-methyl-3-[(4-(3-methyl-3-($ 

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-({[2-(dimethylamino)ethyl]amino}fluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4-[difluoro(pyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

(4-{[methyl(1-methylpyrrolidin-3-yl)amino]methyl}phenyl)-N-{4-methyl-3-[(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

 $\{4-(methylpyrrolidin-3-ylamino) methylphenyl\}-N-\{4-methyl-3-[(4-(3-pyridyl)pyrimidin-3-ylamino)] methylphenyl] methylphenylp$ 

2-yl)amino]phenyl}carboxamide

(4-{[(1 methylpyrrolidin-3-yl)amino]methyl)phonyl) N {4 methyl-3 [(4-(3-

pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4 (pyrrolidin 3 ylamino)methylphenyl}-N-{4 methyl-3-[(4 (3 pyridyl)pyrimidin 2-

yl)aminolphenyl)carboxamide

or a pharmaceutically acceptable salt thereof.

BYCE 313 . BCAD P1 8/51/5009 41:31:40 PW [Eastern Daylight Time] . SVR:USPTO-EFXRF-6/27 . DNIS:2738300 . CSID:6266080397 . DURATION (mm-ss):00-48

Abblication Number: 10/821,382

- 9. A pharmaceutical acceptable salt according to any one of claims 1 to 8 is methanesulfonic acid salt.
- 10. (currently amended) A pharmaceutical composition containing which comprises as an active ingredient a compound of formula (I) according to as defined in any one of claims 1 to 9 8 or a pharmaceutical acceptable salt thereof of the compound, or a hydrate or solvate thereof, of the compound and together with a pharmaceutical acceptable carrier.

11. Canceled

Respectfully submitted,

GUOQING PAUL CHEN

Tel: 626-482-9676

Dated: September 27, 2006